Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. Company
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Real-time Estimate Cboe BZX  -  02:23 2022-09-28 pm EDT
3.215 USD   +3.71%
09/13Invivyd, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
09/13Invivyd, Inc. has Changed its Ticker to IVVD from ADGI
CI
09/13Adagio Therapeutics, Inc. has Changed its Name to Invivyd, Inc
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Invivyd, Inc.
Invivyd, Inc., formerly Adagio Therapeutics, Inc., is a biopharmaceutical company. The company is engaged in developing antibodies to transcend the limits of naturally occurring immunity and provide protection from viral diseases, beginning with COVID-19. Its technology works at the intersection of virology, predictive modeling, and antibody engineering. Its platform approach yields a pipeline of engineered antibodies designed to provide neutralization across past and current SARS-CoV-2 variants of concern, including wildtype, Beta, Delta, and Omicron BA.1, BA.2, BA.5, and BA.2.75. The Company generates a pipeline of products for use in both the prevention and treatment of disease. Its advanced pipeline candidate includes adintrevimab, an investigational monoclonal antibody that is used against multiple variants of concern for the prevention and treatment of COVID-19. The Company also has multiple discovery stage candidates for the prevention of seasonal influenza.

Number of employees : 103 people.
Managers
Name Title Age Since
David Hering Chief Executive Officer & Director 46 2022
Jane Henderson Chief Financial Officer 57 2020
Laura Walker Chief Scientific Officer 37 2020
Rebecca Dabora Chief Technology & Manufacturing Officer 63 2020
Jill Andersen Chief Legal Officer - 2021
Elham Hershberger, Dr. Chief Development Officer 54 2020
Eric W. Kimble Chief Commercial Officer 55 2020
Members of the board
Name Title Age Since
Marc W. Elia Chairman 45 2022
Tomas Jan Heyman Independent Director 66 2021
Terrance G. McGuire Director 64 -
David Hering Chief Executive Officer & Director 46 2022
Michael S. Wyzga Director 66 2021
Redonda Miller, Dr. Director 54 2021
Tamsin Berry Director 40 2022
Clive Meanwell Director 64 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 109,823,173 73,145,099 66.6% 992,648 0.9% 66.6%
Shareholders
NameEquities%
Adimab LLC 26,687,906 24.3%
Mithril Capital Management LLC 11,241,580 10.2%
M28 Capital Management LP 9,248,250 8.43%
Fidelity Management & Research Co. LLC 8,626,571 7.86%
Polaris Growth Management LLC 8,531,700 7.78%
Alphabet Inc. 5,680,785 5.18%
OrbiMed Advisors Private Equity 5,056,000 4.61%
RA Capital Management LP 4,995,807 4.55%
Slate Path Capital LP 3,735,000 3.40%
683 Capital Management LLC 3,603,637 3.28%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Invivyd, Inc.
Sector Bio Therapeutic Drugs